menu
    • menu
    [{"orgOrder":0,"company":"Healios K.K","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Ami Multistem Cell","moa":"Mesenchymal stem cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Healios K.K","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Healios K.K"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Immunology","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Healios K.K","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Healios K.K"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Healios K.K \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Healios K.K \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healios K.K \/ Healios K.K","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Healios K.K"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Medpace, Inc"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Healios K.K \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Medpace, Inc"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Memorial Hermann Hospital | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Memorial Hermann Hospital | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Memorial Hermann Hospital | US Department of Defense"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys | Cell Therapy Catapult","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Athersys | Cell Therapy Catapult","highestDevelopmentStatusID":"9","companyTruncated":"Healios K.K \/ Athersys | Cell Therapy Catapult"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Prof. Dr. Marc-H. Dahlke, Ph. D.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Prof. Dr. Marc-H. Dahlke, Ph. D.","highestDevelopmentStatusID":"6","companyTruncated":"Healios K.K \/ Prof. Dr. Marc-H. Dahlke, Ph. D."}]

    Find Clinical Drug Pipeline Developments & Deals by Healios K.K

    Menu

    Healios K.K

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Athersys

                            Deal Size : $151.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs...

                            Details : Under the terms of the MOU, Athersys grants global rights to Healios to develop and commercialize MultiStem (Invimestrocel) for the treatment of acute respiratory distress syndrome (ARDS).

                            Product Name : MultiStem

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 10, 2023

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Athersys

                            Deal Size : $151.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs

                            Details : MultiStem® cell therapy (invimestrocel) is patented regenerative medicine product has shown ability to promote tissue repair and healing in a variety of ways, such as through production of therapeutic factors in response to signals of inflammation and t...

                            Product Name : MultiStem

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 02, 2022

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic ...

                            Details : MultiStem® cell therapy (invimestrocel) is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic fac...

                            Product Name : MultiStem

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

                            Details : Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.

                            Product Name : MultiStem

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 04, 2022

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment

                            Details : The TREASURE study is a placebo-controlled, double-blind, phase 2/3 trial designed to confirm the efficacy and safety of MultiStem (HLCM051) in treating patients with ischemic stroke.

                            Product Name : MultiStem

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 10, 2021

                            Lead Product(s) : Invimestrocel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Athersys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLCM051

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Athersys

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Athersys Announces Cooperation Agreement With HEALIOS K.K.

                            Details : This agreement will enable both Athersys and Healios to focus on advancing their late-stage programs for MultiStem, including preparing for top line results from Healios’ TREASURE trial for stroke and ONE-BRIDGE trial for ARDS, which is expected this y...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : HLCM051

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Athersys

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Multipotent Adult Progenitor Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Memorial Hermann Hospital | US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

                            Details : Multipotent Adult Progenitor Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 31, 2020

                            Lead Product(s) : Multipotent Adult Progenitor Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Memorial Hermann Hospital | US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Multipotent Adult Progenitor Cell

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

                            Details : Multipotent Adult Progenitor Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Distress Syndrome.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 29, 2020

                            Lead Product(s) : Multipotent Adult Progenitor Cell

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLCM051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS

                            Details : HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : HLCM051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Healios K.K

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLCM051

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan ...

                            Details : The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 09, 2020

                            Lead Product(s) : HLCM051

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth